Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8TBB6
UPID:
S7A14_HUMAN
Alternative names:
Solute carrier family 7 member 14
Alternative UPACC:
Q8TBB6; B3KV33; Q9HCF9
Background:
The Probable cationic amino acid transporter, also known as Solute carrier family 7 member 14, plays a crucial role in arginine transport. This protein's involvement in cellular processes is underscored by its alternative name, highlighting its function in the solute carrier family.
Therapeutic significance:
Retinitis pigmentosa 68, a retinal dystrophy, is directly linked to variants affecting this protein. Understanding the role of the Probable cationic amino acid transporter could lead to novel therapeutic strategies for this debilitating visual impairment.